Alprostadil (suppository)

Alprostadil (suppository)

Clinical data
ATC code	C01EA01 (WHO) G04BE01 (WHO)
Identifiers
IUPAC name 7-[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] heptanoic acid
CAS Number	745-65-3
PubChem CID	149351
DrugBank	APRD00785
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H34O5
Molar mass	354.481 g/mol

WikiDoc Resources for Alprostadil (suppository)
Articles
Most recent articles on Alprostadil (suppository) Most cited articles on Alprostadil (suppository) Review articles on Alprostadil (suppository) Articles on Alprostadil (suppository) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Alprostadil (suppository) Images of Alprostadil (suppository) Photos of Alprostadil (suppository) Podcasts & MP3s on Alprostadil (suppository) Videos on Alprostadil (suppository)
Evidence Based Medicine
Cochrane Collaboration on Alprostadil (suppository) Bandolier on Alprostadil (suppository) TRIP on Alprostadil (suppository)
Clinical Trials
Ongoing Trials on Alprostadil (suppository) at Clinical Trials.gov Trial results on Alprostadil (suppository) Clinical Trials on Alprostadil (suppository) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Alprostadil (suppository) NICE Guidance on Alprostadil (suppository) NHS PRODIGY Guidance FDA on Alprostadil (suppository) CDC on Alprostadil (suppository)
Books
Books on Alprostadil (suppository)
News
Alprostadil (suppository) in the news Be alerted to news on Alprostadil (suppository) News trends on Alprostadil (suppository)
Commentary
Blogs on Alprostadil (suppository)
Definitions
Definitions of Alprostadil (suppository)
Patient Resources / Community
Patient resources on Alprostadil (suppository) Discussion groups on Alprostadil (suppository) Patient Handouts on Alprostadil (suppository) Directions to Hospitals Treating Alprostadil (suppository) Risk calculators and risk factors for Alprostadil (suppository)
Healthcare Provider Resources
Symptoms of Alprostadil (suppository) Causes & Risk Factors for Alprostadil (suppository) Diagnostic studies for Alprostadil (suppository) Treatment of Alprostadil (suppository)
Continuing Medical Education (CME)
CME Programs on Alprostadil (suppository)
International
Alprostadil (suppository) en Espanol Alprostadil (suppository) en Francais
Business
Alprostadil (suppository) in the Marketplace Patents on Alprostadil (suppository)
Experimental / Informatics
List of terms related to Alprostadil (suppository)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alprostadil is the pharmaceutical name for prostaglandin E₁. It is used as a drug in the treatment of erectile dysfunction and has vasodilatory properties.

Sexual dysfunction

Aprostidil is sold in the United States under the brand name Muse. It is also sold as Caverject and Edex.

Muse delivers alprostadil as a penile suppository, inserted into the urethra, at least ten minutes before the erection will be needed. Caverject and Edex are similarly fast-acting, but are actually injected directly into the corpus cavernosum of the penis.

This drug is reputed to work for erectile dysfunction for 30 to 60 minutes.

This drug, following on the coattails of Viagra, has failed to achieve comparable above-ground market share in the United States, perhaps in part because of the invasive means of delivery.

NexMed is developing transdermal forumulations—Alprox-TD(R) for men with erectile dysfunction and Femprox(R) for female sexual arousal disorder. Alprox-TD(R) has been selling in China and in Hong Kong since October 2001 and April 2002, respectively. Two Phase III studies have been completed for this product, and the Company is seeking regulatory approval in the U.S., Canada and Europe.

Other uses

Aprostadil is also used in maintaining a patent ductus arteriosus in the fetus. This is primarily useful when there is threat of premature closure of the ductus arteriosus.